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Abstract
 
Mature dendritic cells (DCs) are believed to induce T cell immunity, whereas immature DCs
induce T cell tolerance. Here we describe that injections of DCs matured with tumor necrosis
factor (TNF)-
 
 
 
 (TNF/DCs) induce antigen-specific protection from experimental autoim-
mune encephalomyelitis (EAE) in mice. Maturation by TNF-
 
 
 
 induced high levels of major
histocompatibility complex class II and costimulatory molecules on DCs, but they remained
weak producers of proinflammatory cytokines. One injection of such TNF/DCs pulsed with
auto-antigenic peptide ameliorated the disease score of EAE. This could not be observed with
immature DCs or DCs matured with lipopolysaccharide (LPS) plus anti-CD40. Three consec-
utive injections of peptide-pulsed TNF/DCs derived from wild-type led to the induction of
peptide-specific predominantly interleukin (IL)-10–producing CD4
 
 
 
 T cells and complete
protection from EAE. Blocking of IL-10 in vivo could only partially restore the susceptibility
to EAE, suggesting an important but not exclusive role of IL-10 for EAE prevention. Notably,
the protection was peptide specific, as TNF/DCs pulsed with unrelated peptide could not pre-
vent EAE. In conclusion, this study describes that stimulation by TNF-
 
 
 
 results in incom-
pletely matured DCs (semi-mature DCs) which induce peptide-specific IL-10–producing T
cells in vivo and prevent EAE.
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Introduction
 
Dendritic cell (DC)
 
*
 
 development has been divided into
the two major stages immature and mature. Immature DCs
reside in peripheral tissues as sentinels of the immune sys-
tem responding to inflammatory stimuli (e.g., TNF-
 
 
 
) or
microbial products (e.g., LPS). Such signals induce matura-
tion and migration of DCs into secondary lymphoid organs
where they now appear as mature DCs expressing high sur-
face levels of MHC II and costimulatory molecules en-
abling efficient T cell priming (1). Further DC-T cell
cross-talk (e.g., via CD40-CD154 interaction) leads to full
DC maturation, cytokine production, and Th1 or Th2 po-
larizations (2). However, these stimuli were also shown to
have different qualities in stimulating DC maturation and
cytokine production (3, 4), which finally might contribute
to differential levels of T cell activation, Th1/2 polariza-
tion, and even T cell tolerance.
Immature DCs residing in peripheral tissues such as epi-
dermal Langerhans cells are poor T cell stimulators because
they express only moderate levels of MHC II (5) and no or
very low levels of costimulatory molecules such as B7–1,
B7–2, intercellular adhesion molecule (ICAM)-1, and
CD40 (6). When we generated such MHC II
 
low
 
/B7
 
neg/low
 
immature DCs from murine bone marrow (BM) and ap-
plied them for antigen presentation to allogeneic T cells,
they induced T cell anergy (7, 8). Human immature DCs
generated from peripheral blood monocytes were shown to
induce IL-10 producing regulatory T cells in vitro (9) and
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in vivo (10). Thus, the interaction of T cells with immature
DCs is believed to cause T cell tolerance by inducing T cell
anergy or IL-10 producing regulatory T cells, while mature
DCs induce T cell immunity.
More recently this view has been challenged by the ob-
servation that DCs could produce IL-10 when treated with
maturation stimuli (11–13) and thereby being tolerogenic.
In vivo, IL-10–producing DCs have been shown to sup-
press experimental autoimmune encephalomyelitis (EAE;
references 14 and 15) or mediate tolerance to intranasally
administered antigens (16). However, most of these IL-10–
mediated effects could also be due to bystander suppression
and may therefore not be antigen specific.
Here we investigate the tolerogenicity of DCs that are
matured with TNF-
 
 
 
 in the murine EAE model. Such
TNF/DCs produce low amounts of inflammatory cyto-
kines and no IL-12 p70 and IL-10. However, after repeti-
tive injections, they induce IL-10–producing T cells and
antigen specifically prevent EAE. We further show that
the capacity of TNF/DCs to prevent EAE is partially IL-
10 dependent and provide data that this cannot be
achieved by immature DCs or DCs matured with LPS
plus anti-CD40.
 
Materials and Methods
 
Generation of Different BM-DCs.
 
DCs were generated from
BM cells derived from C57BL/6 or IL-10
 
 
 
/
 
 
 
 mice (backcrossed
on C57BL/6; reference 17). Cultures were supplemented with
high doses of GM-CSF (200 U/ml; TEBU/PeproTech) or the
10% supernatant of a GM-CSF producing cell line as described
(18). For DC maturation, cultures were pulsed for 4 h with
TNF-
 
 
 
 (500 U/ml; TEBU/PeproTech) or with LPS (1 
 
 
 
g/ml;
Sigma-Aldrich; 
 
E. coli
 
, 0127:B8) with or without anti-CD40
(clone 3/23 or HM40, 5 
 
 
 
g/ml; BD PharMingen) together with
or without 10 
 
 
 
M MOG peptide (see below) before intravenous
injection into the tail vein of mice. To generate immature DCs,
BM cells were cultured continuously in the presence of 20 ng/
ml IL-10 (BD PharMingen; reference 19). DC cultures used for
cytokine detection by ELISA were performed in bacterial qual-
ity 24-well plates (BD Falcon) to avoid DC activation by cell
transfer.
 
FACS
 
®
 
 Analysis, Cell Sorting.
 
BM-DCs were stained with 5
 
 
 
g/ml pure CD40, CD80, CD86 mAb (BD PharMingen), or
undiluted N418 (CD11c), NLDC-145 (CD205), MHC II (M5/
114), and YN1/1.7.4 (CD54) hybridoma supernatants followed
by a 10 
 
 
 
g/ml goat anti–rat IgG and IgM-FITC (Southern Bio-
technology Associates, Inc.) or anti–hamster Ig-FITC (BD
PharMingen), and counterstained with CD11c-PE (all BD
PharMingen), for 30 min on ice before they were analyzed with a
FACScan™ (Becton Dickinson).
Before cell sorting with magnetic beads, spleen cells were
treated with 0.83% wt/vol ammoniumchloride in water for 5
min at 37
 
 
 
C to lyse erythrocytes. To release DCs from spleen
connective tissue the single cell suspensions were treated with 1
mg/ml Collagenase III (Worthington), 100 U/ml DNase I
(Sigma-Aldrich), for 30 min, and 20 mM EDTA (Sigma-Aldrich)
for 5 min as described (20). For enrichment of CD4
 
 
 
 T cells,
positive selection with magnetic CD4-Dynabeads was followed
by a Detachbeads procedure, both according to the company
manuals (Dynal). The purity was generally 
 
 
 
90%. To enrich
 
CD11c
 
 
 
 DCs we used CD11c-conjugated magnetic beads
(MACS; Miltenyi Biotech) according to the manufacturer’s in-
structions. There the enrichment was generally 40–50%.
 
ELISA.
 
Cytokines produced from spleen cells were de-
tected in culture supernatants at the indicated times by using the
ELISA kits for IL-12 p70, IL-12 p40, IL-10, IL-2, IL-4, and
IFN-
 
 
 
 (BD PharMingen). Supernatants from spleen cell restim-
ulations were taken after 24, 48, 72, and 96 h and frozen or
tested immediately. For detection of IL-10, IL-12 p40, and IL-
12 p70 produced by DCs, cells were cultured for 24 h with the
indicated stimuli or 50 ng/ml phorbol-myristate-acetate (PMA;
Sigma-Aldrich) plus 500 ng/ml Ionomycin (Sigma-Aldrich) be-
fore supernatants were analyzed.
 
RNase Protection Assay.
 
Production of cytokine RNA was
induced in DCs for 4, 7, and 24 h by the indicated stimuli and
detected by an RPA kit (BD PharMingen) following the manu-
facturer’s instructions.
 
EAE Induction, Treatment by DCs, and Other Factors.
 
MOG
peptide 35–55 (Sigma Genosys) was used in C57Bl/6 mice to in-
duce EAE. Briefly, C57BL/6 mice were injected subcutaneously
with 50 
 
 
 
g MOG peptide (or additional 50 
 
 
 
g OVA 323–339
peptide in one experiment) in 50 
 
 
 
l PBS emulsified in 50 
 
 
 
l
CFA that was further enriched with 10 mg/ml M. tuberculosis
(H37Ra, Difco/BD PharMingen). In addition 200 ng Pertussis
toxin (List/Quadratech) were injected intraperitoneally at day 0
and 2. The incidence of EAE induced in our mice was through-
out 90%, however the day of EAE onset varied between day
8–11 or day 14–17 depending on the batch of MOG peptide.
Therefore in each experiment an untreated control group was in-
cluded. Paralysis was evaluated according to the following score:
1 
 
 
 
 full tail, 2 
 
 
 
 hind limbs, 3 
 
 
 
 complete back, 4 
 
 
 
 fore limbs
(i.e., complete paralysis, such mice were killed). DCs were in-
jected (2–2.5 
 
 
 
 10
 
6
 
, intravenously) 4 h after stimulation and pep-
tide pulse (see above) once or repeatedly as indicated in the figure
legends. The rat anti–mouse IL-10R mAb (provided by M.
Goldman, University of Brussels, Brussels, Belgium) and an iso-
type-matched control mAb were prepared as a concentrate in a
cell factory (Integra Biosciences) and injected at 0.5 mg equiva-
lents per mouse intraperitoneally at the same days as the DCs (day
 
 
 
7, 
 
 
 
5, 
 
 
 
3) before EAE induction (day 0) and additionally at
day 
 
 
 
1 and day 1.
 
Results
 
Stimulation with TNF-
 
 
 
 Induces DC Maturation but Poor
Cytokine Production.
 
To investigate possible differences
between typical DC stimuli, we treated DCs generated
from murine BM for 24 h with TNF-
 
 
 
, LPS, or LPS plus
anti-CD40. Untreated BM-DCs typically consist of a het-
erogeneous mixture of immature and spontaneously ma-
tured DCs (18) and were not used for further analysis. For
comparison we generated specifically immature DCs by
adding IL-10 throughout the BM-DC culture (19). Imma-
ture DCs expressed no maturation markers (CD205,
CD25) and low levels of MHC II and the costimulatory
molecules CD80, CD86, and CD40 (Fig. 1 a). In contrast,
on mature DCs all of these markers were upregulated, but
comparably high after stimulation with TNF-
 
 
 
, LPS, or
LPS plus anti-CD40 (Fig. 1 a). Except the expression of
CD40 was slightly higher on DCs stimulated with LPS plus
anti-CD40 (Fig. 1 a). 
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However, the production of cytokines varied remarkably
between the differentially stimulated DC. IL-12 p70 and
IL-10 production were completely dependent on LPS
stimulation, and could not be detected after treatment with
TNF-
 
 
 
 alone (Fig. 1 b). Basic levels of IL-12 p40 were
produced by all types of DCs but strongly augmented by
LPS. In addition, mRNA for IL-10 was not detectable in
TNF/DCs by reverse transcription (RT)-PCR after 6 and
16 h (not shown) or by RPA after 4 and 7 h (not shown)
or 24 h (Fig. 1 c). The mRNA levels for IL-1
 
 
 
 and IL-6
were low in DC cultures matured with TNF-
 
 
 
 or LPS
alone but highly increased in cultures stimulated with LPS
plus anti-CD40 (Fig. 1 c).
This shows that the quality of maturation stimuli for DCs
varies predominantly on the level of cytokine production
but not on the expression of surface markers. Therefore we
compared the cytokine
 
weak
 
 TNF/DCs (semi-mature or in-
completely matured), cytokine
 
strong
 
 LPS/CD40/DCs (fully
mature), and immature DCs for their capacity to influence
EAE after auto-antigenic MOG peptide pulse.
 
Peptide-specific Prevention of EAE by Repetitive Injections of
TNF/DCs.
 
Immature DCs, generated by various meth-
ods, have been shown to induce T cell anergy or regulatory
T cells and that they can act in tolerogenic fashion in mice
(8, 21, 22), rat (14), and human (10). Therefore, we gener-
ated immature DCs by the continuous presence of IL-10
(19), pulsed them with the auto-antigenic MOG peptide
35–55, and injected them intravenously into mice 3 d be-
fore EAE induction. However, the EAE score was not in-
fluenced by these immature DC (Fig. 2 a) or MOG-pulsed
DCs matured with LPS plus anti-CD40 (Fig. 2 b). Also
three injections of MOG/LPS/CD40/DCs did not prevent
EAE (not shown). Surprisingly, a single injection of MOG-
pulsed TNF/DCs given 3, 5 (not shown), or 7 d before
EAE induction ameliorated the course of the disease (Fig. 2
c), and three injections led to complete prevention of the
disease. This prevention from EAE was dependent on the
loading of TNF/DCs with MOG peptide and was not ob-
served by unloaded TNF/DCs (Fig. 2 d) or when TNF/
DCs were pulsed with irrelevant OVA peptide.
 
TNF/DCs Induce Antigen-specific IL-10–producing CD4
 
 
 
T Cells.
 
To assess the mechanism of complete EAE sup-
pression in mice that received three injections with MOG/
TNF/DCs or MOG/LPS/CD40/DCs their spleens were
removed at day 0 and restimulated with MOG peptide or
irrelevant OVA peptide, and the culture supernatants were
analyzed after 24, 48, 72, and 96 h for their cytokine con-
tent. The predominant cytokine that could be detected af-
ter three MOG/TNF/DCs injections was IL-10, whereas
only little IFN-
 
 
 
 and no IL-2 or IL-4 were present (Fig. 3
a). Preliminary data indicate that also TGF-
 
 
 
1 is absent
(not shown). In contrast, three injections of MOG/LPS/
Figure 1. Surface phenotype and cytokine production of DCs matured with TNF- . (a) DCs were generated from C57BL/6 mice until day 8 in the
presence of IL-10 to inhibit their maturation, or in the absence of IL-10 and additional stimulation with TNF-  or anti-CD40 plus LPS overnight.
FACS® analysis shows the expression of the indicated markers (straight line) or isotype controls (dotted line) of CD11c  cells within a life gate. Numbers
within histograms represent the mean fluorescence of the marker with subtracted isotype values. (b) DCs were cultured in a 24-well plate until day 8.
Then, cells were stimulated without transfer for 24 h with TNF- , anti-CD40, LPS, or their combinations, before supernatants were tested for their cy-
tokine content by ELISA. (c) DCs were stimulated at day 8 as indicated and harvested after 24 h. The levels of mRNA expression were detected by
RNase protection assay. The data for (a) is representative of more than six, and the data for b and c are each representative of three independent experi-
ments with similar results. 
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CD40/DCs induced predominantly IFN-
 
 
 
 but no IL-2,
IL-4, or IL-10, indicative for the induction of a Th1 re-
sponse, which could explain why such DCs are not protec-
tive in the Th1-mediated EAE.
Although TNF/DCs were not found to produce sizable
amounts of IL-10 after in vitro stimulation (Fig. 1, b and c),
we analyzed whether the IL-10 produced from the spleen
cell suspensions was secreted by the DCs we injected, or
endogenous DCs, or T cells. Mice were injected three
times with TNF/DCs and at day 0 their spleen cells were
sorted for CD4
 
 
 
 and CD11c
 
 
 
 cells and stimulated with
PMA plus Ionomycin. The sorted CD11c
 
 
 
 DCs from
untreated and TNF/DC injected mice produced small
amounts of IL-10 in the same range (Fig. 3 b). However,
much higher levels of IL-10 were secreted by sorted
CD4
 
 
 
CD3
 
 
 
 T cells after injection of TNF/DCs (Fig. 3 b).
T cells of mice that were not injected with DCs did not se-
crete IL-10. To test whether a potential IL-10 production
by the TNF/DCs could anyhow influence EAE preven-
tion, we also injected MOG-pulsed TNF/DCs derived
from IL-10
 
 
 
/
 
 
 
 mice. However, wild-type and IL-10
 
 
 
/
 
 
 
TNF/DCs were equally potent to completely prevent EAE
symptoms (not shown).
Together, our data indicate that the major source of IL-
10 after repetitive TNF/DC injections and spleen cell re-
stimulation with MOG peptide are CD4
 
 
 
CD3
 
 
 
 T cells.
 
EAE Prevention Is Partially Dependent on IL-10.
 
As IL-
10 was the major cytokine detected after repetitive TNF/
DC injections, we tested whether IL-10 blockade in vivo
could influence the protection from EAE. Therefore, we
injected mice treated with our standard TNF/DC injec-
tions and EAE protocol with anti–IL-10R mAb or isotype
control mAb. In animals receiving anti–IL-10R, but not
with isotype control mAb, the protection from EAE was
partially reverted (Fig. 3 c). Together these data imply that
TNF/DCs induce IL-10 producing CD4
 
 
 
 T cells in vivo.
When this IL-10 production is blocked by anti–IL-10R the
protection is reverted and the mice develop a mild form of
EAE. This partial effect of anti–IL-10R might be indicative
for other regulatory mechanisms.
 
Discussion
 
Increasing evidence indicates that DCs are not only deci-
sive for T cell priming, but are also key players to maintain
self-tolerance in vivo. The general view is that immature
DCs are tolerogenic while mature DCs are immunogenic.
This is based on experiments in mice where DC matura-
tion was inhibited by certain substances or protocols and
such immature DCs induced T cell anergy in vitro (8, 19)
and influenced allogeneic transplantations (7, 23). The
tolerogenicity by these immature DCs was attributed to the
absence or low level expression of costimulatory molecules.
However, more recently it has been clearly shown that co-
stimulation is definitely required for the induction of T cell
anergy (24) as well as for the generation of regulatory T
cells (25). Thus, DCs expressing higher amounts of MHC
and costimulatory molecules must not necessarily be im-
munogenic. We found evidence that the quality of the DC
maturation stimulus regulating their cytokine production
and the repetitive mode of application might also be deci-
sive features for tolerogenicity of DCs.
Figure 2. Repetitive injections of TNF/DCs protect
mice from EAE DCs were simultaneously pulsed with
MOG peptide and treated with TNF-  for 4 h (MOG/
TNF/DC), washed in PBS, and 2.5   106 cells were in-
jected once (1 ) or three times (3 ) intravenously into
3–4 C57BL/6 mice per group. Control mice were left
without DC injections (untreated). 3 d after the last/only
DC injection EAE was induced and the mice observed
for paralysis. (a) Injection of immature DCs, generated in
the presence of IL-10, pulsed with MOG peptide, and
injected 3 d before EAE induction, were not protective.
(b) DCs matured with LPS plus anti-CD40 and pulsed with MOG peptide and injected before EAE induction were not protective. (c) Single injections
of MOG pulsed and TNF-  matured DCs, given 7 d before EAE induction, could ameliorate the disease. (d) Three injections of MOG-pulsed TNF/
DC but not unpulsed TNF/DC given at days  7,  5, and  3 before EAE induction completely protected mice from EAE. (e) OVA/TNF/DCs could
not protect from EAE. As a peptide specificity control, three injections of OVA-pulsed TNF/DC were given at days  7,  5, and  3 before EAE in-
duction or mice were left untreated. OVA peptide was additionally emulsified together with the MOG peptide in CFA at day 0 in this experiment. The
data for a–d are each representative of three independent experiments with similar results. 
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The maturation signals delivered through TNF-
 
 
 
, anti-
CD40, or LPS differ remarkably in their quality to stimu-
late the cytokine production by DCs (3, 4), and the effects
of a certain cytokine might be further modulated when dif-
ferent receptor types exist for this cytokine, as shown for a
tolerogenic role of TNF-
 
 
 
 when acting through its TNF-
receptor-2 (26). Here, DCs matured with TNF-
 
 
 
 pro-
tected from EAE, but not DCs matured with LPS plus
anti-CD40. This tolerogenic capacity of TNF/DCs was
correlated with a low proinflammatory cytokine produc-
tion when compared with LPS/CD40/DCs. In how far
this is relevant for the EAE protection in our system, needs
further investigation. Taken together, TNF-
 
 
 
 seems to in-
duce an incomplete DC maturation with respect to their
cytokine production which correlates with a rather tolero-
genic type of DC.
More recent work described DC types that can produce
IL-10 and thereby control autoimmunity, as shown for the
prevention of EAE (14, 15) or induction of mucosal toler-
ance (16). For the latter it has been shown that the IL-10
producing DC expressed a 
 
mature
 
 surface marker profile
and that they induced IL-10 producing regulatory T cells.
These murine data seem different from data derived from
human 
 
immature 
 
monocyte-derived DCs which constitu-
tively express IL-10 mRNA (27) and low amounts of IL-
10 protein which could be further induced by stimulation
with anti-CD40 or LPS (13). Although in other studies
such immature monocyte-derived DCs were not investi-
gated for IL-10 production, they, similarly to the murine
data, induced IL-10 producing T cells (9, 10). It is of note
that the DCs in their so-called immature state already ex-
press substantial amounts of MHC II and costimulatory
molecules, and thereby resemble more the incompletely
matured/semi-mature TNF/DCs rather than the immature
IL-10/DCs that we used in this study. Together the re-
quirements for the induction of IL-10 producing regula-
tory T cells by DC in vitro and in vivo seem to be a certain
grade of DC maturity and their capacity to produce IL-10.
However, when we generated TNF/DCs from IL-10
 
 / 
mice they induced IL-10 production by T cells and pre-
vented EAE (not shown).
While a single injection of TNF/DCs ameliorated
EAE, three injections were required for full protection,
indicating that repetition of antigen presentation is impor-
tant. Repetitive stimulation seems to be required to enrich
or expand regulatory T cells in vitro (9), but a single in-
jection can already be effective in vivo (10), indicating
that the maturation state of DCs is more important and
repetition might solely enhance the effects revealed by a
single injection.
Figure 3. Repetitive injections of TNF/DCs induce peptide-specific CD4  T cells producing IL-10 which is partially involved in EAE protection. (a)
TNF/DCs induce IL-10–producing cells from restimulated spleen cells. C57BL/6 mice received three intravenous injections of MOG-pulsed TNF/DCs
or LPS/CD40/DCs at days  7,  5, and  3. Spleen cells from these mice were restimulated at day 0 with 10  M MOG peptide or 10  M unrelated
OVA peptide. Cell supernatants were taken after 24, 48, 72, and 96 h and tested for their cytokine content by ELISA. (b) The IL-10 production from
spleen cells induced by DC injections is derived from CD4 CD3  T cells, but not CD11c  DCs. C57BL/6 mice received three injections of MOG
pulsed TNF/DC at days  7,  5, and  3. Spleen cells from these mice were sorted for CD4  and CD11c  cells at day 0 and then stimulated for 24 h
with PMA plus Ionomycin before supernatants were tested by ELISA for their IL-10 content. From the CD4  enriched cells 97% coexpressed CD3, and
the contamination CD11c  cells within the CD4  cells was 0.8–1.4%. (c) The protection from EAE partially depends on IL-10. C57BL/6 mice (3–4 per
group) were injected three times with MOG/TNF/DCs at days  7,  5, and  3 (3 ) and EAE was induced at day 0. Mice were injected intraperito-
neally with anti–IL-10R mAb or isotype mAb at the same days as TNF/DCs and additionally at day  1 and day 1. Control mice remained without pre-
treatment by DCs and were not injected with mAb. The data for (a) is representative of three, and the data for b and c are each representative of two in-
dependent experiments with similar results.20 Tolerogenicity of Semi-mature DCs
Although the induction of suppressive activities by regu-
latory T cells seem to need antigen-specific stimulation,
their effects mediated through IL-10, TGF- , or cell–cell
contacts can act also through bystander suppression (28, 29).
For the prevention of EAE in other studies (14, 15) or in-
duction of mucosal tolerance (16) by IL-10 producing DCs,
no controls with unrelated peptides were included to show
antigen specificity. Here, we found that TNF/DCs induce
peptide-specific prevention from EAE, which cannot be
due to bystander suppression since OVA-pulsed TNF/DCs
were unable to influence EAE. The immunological dis-
crimination between foreign- and self-antigens, dangerous
and harmless influences in vivo is especially important on
the level of DCs to maintain self-tolerance. Therefore, the
maturation stage of TNF/DC presenting antigens which
induce IL-10–producing T cells, possibly represent a toler-
ance mechanism also relevant in immune-physiology.
The in vivo counterparts that most closely resemble our
in vitro generated TNF/DCs are the “veiled cells” of the
lymphatics, which migrate to the peripheral lymph nodes
transporting tissue antigens (30) or apoptotic cells (31) and
there finally represent a distinguishable subset of skin de-
rived DC (32). In all these reports both veiled cells and
skin-derived DCs express a remarkably mature morphol-
ogy (veiled!) and surface phenotype (MHC IIhighCD80 
CD86 CD40 ). As both types of veiled cells and skin-
derived DCs are detectable under healthy steady-state con-
ditions, they might actively induce tolerance to peripheral
tissue antigens in the draining lymph nodes and spleen (33,
34). The signals which induce the homeostatic DC migra-
tion are unclear. TNF-  might be a likely candidate to be
involved in tolerogenic homeostasis. Besides its potential
tolerogenic role (26), it also promotes DC migration (35),
induces antigen processing (36), and upregulates CC che-
mokine receptor (CCR)7 to guide DCs into the T cell ar-
eas of the draining lymph nodes (37). Thus, TNF-  would
fulfill the prerequisites for promoting steady-state migration
and tolerogenic antigen presentation in the secondary lym-
phoid organs.
In summary, we show that the stimulation of DCs by
TNF- , but not LPS plus anti-CD40, induces incomplete
DC maturation (semi-maturation). Repetitive injections of
such TNF/DCs are able to induce peptide-specific IL-10
producing CD4  T cells in vivo and to prevent EAE in
mice. Generation of such peptide-specific TNF/DCs may
also lead to the development of strategies against human
autoimmune diseases.
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